A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

ClinicalTrials.gov ID: NCT05980806

Public ClinicalTrials.gov record NCT05980806. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 28, 2026, 9:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The main purpose of this study is to evaluate the efficacy of selinexor in JAKi-naïve participants with myelofibrosis (MF) and with normal platelet counts or with mild to moderate thrombocytopenia based on spleen volume reduction (SVR). Additional efficacy and safety parameters will also be assessed during the study.

Study identification

NCT ID: NCT05980806
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Karyopharm Therapeutics Inc; Industry
Enrollment: 58 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 21, 2024
Primary completion: May 31, 2027
Completion: Sep 30, 2028
Last update posted: Feb 11, 2026

2024 – 2028

United States locations

U.S. sites: 7
U.S. states: 7
U.S. cities: 7

Facility	City	State	ZIP	Site status
City of Hope - Duarte Main Site	Duarte	California	91010	Recruiting
Maryland Oncology Hematology - Independent of SCRI/ US Oncology	Columbia	Maryland	21044	Recruiting
Weill Cornell Medicine NewYork-Presbyterian	New York	New York	10021	Recruiting
Duke University	Durham	North Carolina	27705	Recruiting
Cleveland Clinic	Cleveland	Ohio	44195	Recruiting
MD Anderson	Houston	Texas	77030	Recruiting
Huntsman Cancer Institute	Salt Lake City	Utah	84112	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 63 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05980806, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 11, 2026 · Synced Jul 28, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05980806 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →